Advaxis Announces Filing for USDA Product License
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Outlook Therapeutics (OTLK) halted, news pending
Advaxis (ADXS) Reports Filing for ADXS-cHER2 Patent License (PETX)
July 2, 2014 8:36 AM EDTAdvaxis (Nasdaq: ADXS) announced that a product license from the United States Department of Agriculture (USDA) has been filed for ADXS-cHER2, its proprietary Her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma and other HER2-overexpressing cancers. The filing was submitted by Aratana Therapeutics, Inc. (Nasdaq: PETX), which was granted exclusive worldwide rights by Advaxis to develop and commercialize ADXS-cHER2 (also known as AT-014 by Aratana) in animals. While the USDA has no specific obligation to... More
